BUB1 and cancer: Here, we explored the potential of the mitotic checkpoint kinase BUB1 expression as a cancer biomarker and particularly its association with drug responses, stemming from previous studies on BUB1 dysregulation in cancer and its potential exploitation for therapeutic purposes34–37.